# Dana-Farber Cancer Institute

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/dana-farber-cancer-institute
Canonical HTML page: https://getbiobrief.com/entity/dana-farber-cancer-institute

## Recent coverage (1 stories)

### Rasonque Approved: KRAS Inhibitor Doubles Survival to 13.2 Months
2026-08-27 02:32:05 · Sentiment: Strongly positive · Impact: 8/10 · Sources: 2

For biotech and pharma professionals, Revolution Medicines' daraxonrasib becomes the first approved multi-RAS inhibitor, with Phase 3 median overall survival of 13.2 months vs 6.6 on chemo, validating the RAS(ON) platform and opening a new commercial front in pancreatic cancer.
Full story: https://getbiobrief.com/story/rasonque-fda-approval-kras-revolution-medicines

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.